TGF-β is overexpressed in advanced human cancers. It correlates with metastasis and poor prognosis. However, TGF-β functions as both a tumor suppressor and a tumor promoter. Here, we report for the fi rst time that genetic deletion of Tgfbr2 specifi cally in myeloid cells ( Tgfbr2 MyeKO ) signifi cantly inhibited tumor metastasis. Reconstitution of tumor-bearing mice with Tgfbr2
INTRODUCTION
TGF-β signaling plays an important role in tumor initiation and progression. Paradoxically, TGF-β can function as both a tumor suppressor and promoter ( 1, 2 ) . The mechanisms underlying the dual role of TGF-β are very intricate and are poorly understood. In the past, most of the work dissecting the molecular mechanisms was focused on differential regulation of signaling pathways by tumor autonomous TGF-β signaling and cross-talk with other signaling networks (2) (3) (4) . It was thought that changes in the signal intensity and connectivity of SMAD-dependent and -independent pathways, including phosphoinositide 3-kinase (PI3K), mitogenactivated protein kinase (MAPK), as well as small GTPases, might explain the complex transition of TGF-β from a tumor suppressor to a tumor promoter ( 5 ) .
Interestingly, disruption of TGF-β signaling in a number of epithelial cells results in a more malignant tumor phenotype in breast, intestinal, pancreatic, and colon cancers, and in head and neck squamous cell carcinoma ( 6 ) . Deletion of Tgfbr2 , the gene encoding TGF-beta receptor II (TβRII), in FSP1 + fi broblasts induces the development of invasive squamous cell carcinoma in the forestomach and intraepithelial neoplasia in the prostate ( 7, 8 ) . In addition, deletion of SMAD4, an important downstream mediator of TGF-β signaling in T cells, induces development of gastrointestinal cancers ( 9 ) . These studies suggest that TGF-β signaling in epithelial cells, fi broblasts, and T cells has a tumor-suppressive function. Recent work from our group and others showed that downregulation of TGF-β signaling, a frequent event observed in many tumor types, leads to increased CXCL1-CXCL5/CXCR2 and SDF-1/CXCR4 chemokine/chemokine receptor signaling, and subsequent recruitment of host-derived immature myeloid Gr-1
+

CD11b
+ cells or myeloid-derived suppressor cells (MDSC) and macrophages ( 10, 11 ) into tumors. These infi ltrating myeloid cells produce large quantities of TGF-β1 and matrix metalloproteinases (MMP) that suppress the host immune system and concurrently promote tumor invasion ( 10 ) . Myeloid cells play an important role in tumor progression. They suppress host immune surveillance (12) (13) (14) (15) and infl uence the tumor microenvironment ( 10 , 13 , 14 , 16 ) . These cells are also present in the lungs before tumor cell arrival and contribute to premetastatic niche formation ( 17 ) and alteration of the local lung environment ( 18 ) One of the most important properties of these cells is increased TGF-β production ( 10 , 19 ) . In fact, depletion of Gr-1
+
CD11b
+ cells diminished the antitumor effect of TGF-β neutralization, suggesting that immature Gr-1
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report, we show that TGF-β signaling in myeloid cells of tumorbearing hosts is fundamentally important for tumor metastasis. Genetic deletion of Tgfbr2 specifi cally in myeloid cells dramatically decreases tumor metastasis. Our data implicate myeloid TGF-β signaling as a potential novel therapeutic target.
RESULTS
Increased Expression of TbRII in Myeloid Cells under Tumor Conditions, and LysM-Cre-Mediated Myeloid-Specifi c Tgfbr2 Deletion
To assess the role of TGF-β signaling in tumor-associated myeloid cells, we used Gr-1 + CD11b + cells as samples for myeloid cells, as they constitute the majority of tumor-associated myeloid cells and produce high levels of TGF-β1. We used murine 4T1 mammary tumor and Lewis lung carcinoma (LLC) mouse models that are in Balb/c and C57Bl/6 backgrounds, respectively. For both models, we found that splenic Gr-1
+
CD11b
+ cells from tumor-bearing mice express significantly higher levels of TβRII compared with their nontumorbearing counterparts ( Fig. 1A and B ; data not shown for LLC model). The impact of elevated TβRII expression is likely amplifi ed, as the frequencies of these myeloid cells are also increased in the bone marrow, spleen, and peripheral blood of tumor-bearing mice ( Supplementary Fig. S1A ).
The overproduction of immature myeloid cells has also been reported in patients with a variety of cancers ( 16 , 21 ) , in which they are identifi ed as CD33 + , CD34 + , or CD15 + cells ( 16 , 22 , 23 ) . We used these markers to enrich the myeloid cells from the peripheral blood of 16 patients with metastatic non-small cell lung cancer. These myeloid cells, which include granulocytes, monocytes, and their precursors, accounted for approximately 82% of the total leukocytes, compared with 72% from healthy individuals ( n = 11; P < 0.05; Supplementary Fig. S1B ). Sorted myeloid cells from patients showed increased TβRII expression compared with healthy individuals ( Fig. 1C ) . Further examination of human breast cancer and lung cancer datasets using GeneSpring GX 10.0 software showed a signifi cant increase in TβRII and TGF-β1 mRNA in human peripheral blood mononuclear cells of patients with breast cancer compared with normal individuals ( Fig. 1D ; GSE27567 ; ref. 24 ) . In lung cancer, TGF-β1 was increased at stages IIIA and IV compared with stages I and II, and correlated well with the modestly increased TβRII mRNA level ( P > 0.05, but with a trend of increase) in the lung cancer patient cohort (GSE20189; ref. 25 ; Fig. 1D ). Together, these data suggest that increased TβRII expression correlates with cancer progression in a clinical setting.
The overexpression of TβRII in both human and mouse myeloid cells from cancer hosts raised the possibility that TβRII signaling in myeloid cells affects tumor progression and metastasis. Although TGF-βR3 has been recently implicated in tumor progression ( 26, 27 ) , the TGF-β-induced and TGF-βR3-mediated responses have not been shown to be independent of TβRII. On the other hand, overwhelming data from the fi eld support a central role of TβRII in TGF-β signaling. Thus to test our hypothesis, mice with a targeted deletion of Tgfbr2 in myeloid cells ( Tgfbr2 MyeKO ) were generated through the cross-breeding of fl oxed Tgfbr2 ( Tgfbr2 fl ox/fl ox ) mice with LysM-Cre transgenic mice. LysM-Cre transgenic mice have been well characterized and used in many studies to delete genes specifi cally in myeloid cells ( 28, 29 ( Fig. 1E ) , clearly decreased TβRII expression, and phosphorylation of SMAD2 ( Fig. 1F and G ) . These data support that Tgfbr2 deletion was effi cient and specifi c in myeloid cells. MyeKO mice showed a decreased ability to develop tumor metastasis following injection of 4T1 mammary tumor cells into the #2 mammary fat pads (MFP; Fig. 2A ) , with a modest effect on 4T1 primary tumor growth ( P > 0.05) and later stage of LLC growth ( P < 0.05; Supplementary Fig. S2A and S2B). The 4T1 mammary tumor model shares many characteristics with human breast cancer, particularly its ability to spontaneously metastasize to the lungs. In an experimental metastasis design in which 2 × 10 5 4T1 cells were injected into the tail vein, there was also a signifi cant reduction in metastasis in Tgfbr2
Deletion of Tgfbr2 in Myeloid Cells Signifi cantly Inhibited Tumor Metastasis
MyeKO mice ( Fig. 2B ). This result was recapitulated in the B16 melanoma orthotopic and LLC experimental metastasis models in Tgfbr2
MyeKO mice in a C57BL/6 background ( Fig. 2C and  D ) . Similar to the 4T1 tumor model, the primary tumor growth of B16 cells was not different between Tgfbr2
MyeKO and control mice (data not shown). Together, these data suggest that the major effect of myeloid Tgfbr2 deletion is on tumor metastasis. This was supported by two additional experimental metastasis tumor models, MC26 colon cancer and B16 melanoma, which showed a signifi cantly decreased number of lung metastases in Tgfbr2
MyeKO mice compared with controls after tail vein injection of the tumor cells (Supplementary Fig. S2C and S2D ).
To further confi rm the inhibitory effect of myeloid-specifi c Tgfbr2 deletion on tumor metastasis, we transplanted bone marrow from Tgfbr2
MyeKO mice into wild-type mice bearing 4T1 tumors. To better model clinical metastatic disease, the primary tumor was surgically removed on day 15 and metastasis was allowed to continue until day 34, when the animals were irradiated and subjected to bone marrow transplantation ( Fig. 2E ). In these therapeutic experiments, 4T1 tumors were injected into the #4 MFP to allow surgical removal of tumors. We observed 100% survival of the mice that received bone marrow from the Tgfbr2 MyeKO mice, whereas approximately 55% of the mice that received bone marrow from Tgfbr2 fl ox/fl ox control mice showed decreased survival ( Fig. 2F ). In addition, a signifi cant reduction in the number of lung metastases was observed in mice that received Tgfbr2 MyeKO bone marrow relative to those that received control bone marrow ( Fig. 2F ). These data suggest that myeloid-specifi c TGF-β signaling constitutes an essential part of the metastasispromoting role of TGF-β. 
CD11b
+ cells were used for protein extraction or cytospin slides. Cells from mice bearing 4T1 tumors (Tu) were compared with nontumor-bearing normal mice (Nor). Scale bar, 20 μm. C, TβRII Western blotting of sorted human blood myeloid cells enriched using CD33 MyeKO mice following subcutaneous injection of B16 melanoma cells (1 × 10 6 ; n = 7). Tumors were resected on day 16, lungs were harvested on day 37. *, P < 0.05. D, a dramatic reduction of lung metastasis in Tgfbr2
MyeKO mice on a C57BL/6 background that received tail vein injection of LLC cells (2.5 × 10 5 ; n = 5-6 mice). Quantitative data are on the right. One of two experiments is shown. **, P < 0.01. E, schematic experimental design for adoptive transfer of Tgfbr2
MyeKO bone marrow to wild-type 4T1 tumor-bearing mice. F, Kaplan-Meier survival curve (left) and metastasis counts (right) in mice that received bone marrow transplant from Tgfbr2
MyeKO and fl oxed control mice. Shown is one of two experiments carried out. *, P < 0.05. All data are represented as mean ± SEM. 
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Deletion of Tgfbr2 in Myeloid Cells Decreased Type II Cytokine Expression and Increased IFN-g Production and Host Antitumor Immunity
TGF-β signaling is a critical mediator of immune cell polarization ( 19 ) . It is not clear whether it has similar function in myeloid cells. We examined type I and II cytokine expression in sorted Gr-1 + CD11b + cells. Interestingly, the expression of type II cytokines, including interleukin (IL)-10 and IL-4, was reduced in myeloid cells with Tgfbr2 deletion compared with controls, with no difference in type I cytokine production (e.g., IL-12 and TNF-α; Fig. 3A ).
There was also reduced expression of arginase 1 and inducible nitric oxide synthase (iNOS; Fig. 3A ), the critical mediators implicated in the immune suppression effects of Gr-1 + CD11b + cells. The decreased expression of type II cytokines was further confi rmed in a cytokine protein array ( Fig. 3B , top; with semiquantitative data of dot density at the bottom). Deletion of myeloid Tgfbr2 also decreased TGF-β1 production in sorted Gr-1
suggesting an autocrine effect of TGF-β signaling. The decreased expression of iNOS and arginase 1 is consistent with decreased nitric oxide (NO) production and arginase 1 activity ( Fig. 3D ).
Tumor-associated myeloid cells inhibit multiple immune cell functions in tumor hosts ( 12 ) . We therefore examined whether deletion of myeloid-specifi c Tgfbr2 resulted in improved immune function of CD4 
Local Innate Immunity in Premetastatic Lung Microenvironment of Tgfbr2 MyeKO Mice
Tgfbr2 MyeKO mice showed a decreased ability to develop tumor metastasis following tail vein injection of a number of tumor cell types, including 4T1 ( Fig. 2B ) , LLC ( Fig. 2D ) , MC26, and B16 (Supplementary Fig. S2C and S2D Fig. S6B ). This is consistent with previous reports ( 30, 31 MyeKO and control mice bearing 4T1 tumors. Shown is the mean ± SEM of three samples per group. *, P < 0.05; **, P < 0.01; ***, P < 0.001. B, cytokine protein array analysis of sorted Gr-1 + myeloid cells (top), with semiquantitative data of dot density below. Shown is one of two experiments carried out. ***, P < 0.001. C, TGF-β1 ELISA of Gr-1 + myeloid cells sorted from the spleen of 4T1 tumor-bearing mice. Samples from three mice were collected and triplicates per sample were analyzed. D, decreased NO production and arginase 1 function. Samples were from 4T1 tumor-bearing Tgfbr2
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MyeKO and control mice. *, P < 0.05; **, P < 0.01. Therefore, the effect from the CD11b + Ly6G + cells is likely major.
To further confi rm the effect of these myeloid cell subsets in vivo , we injected sorted wild-type myeloid cell subsets into 4T1 tumor-bearing Tgfbr2
MyeKO mice through the tail vein. We fi rst tested the homing effi ciency of tail vein-injected cells using luciferase imaging. Approximately more than 65% to 75% of the luciferase-expressing 4T1 cells injected through the tail vein homed to the lungs 24 hours after Fig. S10A ). We found that the injection of CD11b + Ly6G + cells reversed the metastasis defect in Tgfbr2 MyeKO mice ( Fig. 6D ). These data suggest that the CD11b + Ly6G + myeloid subset is responsible for the inhibition of metastasis that results from the myeloid-specifi c deletion of Tgfbr2 . Our conclusion may more broadly apply to mouse models in which CD11b + Ly6G + myeloid cells constitute the majority of myeloid cells, including at least eight tumor models studied, such as MC26 colon cancer, LLC, and B16 melanoma ( 32 ).
Cellular Mechanisms Underlying Improved Host Antitumor Immunity and Decreased Metastasis in Tgfbr2 MyeKO Mice
Our data clearly show an IFN-γ-dependent mechanism in inhibiting metastasis in Tgfbr2
MyeKO mice. We next asked the question, what cell type (CD8 + T or Ly6G + neutrophils)
is critical in this process? Tgfbr2 MyeKO mice were inoculated with 4T1 tumor cells in the MFP. The mice were also injected with CD8-neutralizing antibody or immunoglobulin G (IgG) control every 2 to 3 days to deplete CD8 + T cells ( Fig. 7A ) . The depletion of CD8 + T cells in Tgfbr2 MyeKO mice diminished the metastasis inhibition compared to the IgG control-treated mice ( Fig. 7B ). In addition, to examine the direct contribution of myeloid-derived IFN-γ in the inhibition of the metastasis in the lung environment, we sorted IFN-γ-defi cient or wild-type CD11b 
DISCUSSION
We report here for the fi rst time that deletion of Tgfbr2 specifi cally in myeloid cells signifi cantly inhibited tumor metastasis, suggesting that myeloid-specifi c TGF-β signaling is an essential component of the metastasis-promoting puzzle of TGF-β. This is in contrast to the tumor-suppressing effect of TGF-β in epithelial cells, fi broblasts, and T cells ( 6, 7 , 9 , 33 + Ly6G + and CD11b+Ly6C myeloid cell subsets. For both A and B, myeloid subsets were sorted by fl uorescenceactivated cell sorting (FACS). RNA was extracted and subjected to qPCR analysis. Supernatant from cultured subsets was used for ELISA. Myeloid cells were isolated from the spleens of 4T1 tumor-bearing mice. C, NO production of myeloid cell subsets sorted from Tgfbr2
MyeKO mice (C57BL/6 background), when cocultured with OVA peptide-stimulated splenocytes from OT1 mice (C57BL/6 background). For A-C, three mice each for Tgfbr2 MyeKO mice ( n = 7-10). All data are represented as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
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insight into TGF-β regulation of tumor metastases. Our data are reminiscent of those observed following blockade of TGF-β signaling in T cells using CD4dnTGF-β-RII mice, which confers resistance to an EL-4 lymphoma or a B16-F10 melanoma tumor challenge ( 34 ) . However, those mice developed an autoimmune pathology that is not seen in our mouse model. The lack of pathology in our mouse model is likely due to the fact that myeloid cells are signifi cantly expanded under tumor conditions (Supplementary Fig.  S1A ). Therefore, the specifi c deletion of myeloid Tgfbr2 produces a pronounced antitumor effect with very few adverse effects. A previous report showed CD8
+ CTL-mediated suppression of melanoma and prostate metastasis upon the silencing of TGF-β signaling in total bone marrow cells by retroviral-mediated transfection of a dominant-negative TβRII ( 35 ) . Our fi ndings indicate that the myeloid cell-associated TGF-β signaling may be the key player driving this effect.
Our studies show that TGF-β signaling is a critical mediator of the tumor-promoting effect of myeloid cells, supported by a recent report of the antitumor properties of myeloid Tgfbr2 deletion on primary tumor growth ( 36 ) . Myeloid cells have been shown to promote tumor progression through modulation of host immune surveillance (12) (13) (14) (15) and alteration of the tumor microenvironment ( 10 , 13 , 14 , 16 ) . Recent evidence also suggests that myeloid cells have a substantial impact on the premetastatic lung ( 17, 18 , 37, 38 ) . A number of studies have tried to identify the molecular mechanisms for these myeloid cells in tumor metastasis. One of the better-studied molecules involves the paracrine loop of colony-stimulating factor 1 (CSF-1) and EGF between tumor cells and TAMs ( 13 , 39 ) . Apparently, CSF-1 is produced by tumor cells and acts on the CSF-1R on TAMs ( 40, 41 ) . Interestingly, tumor cells also express EGF receptor that mediates the signaling of EGF produced by TAMs ( 39 , 41-43 ) . These two molecular pathways are critical for the effects of TAMs upon tumor metastasis ( 13 , 39 ) . Hypoxia-inducible factor 1α (HIF-1α) in myeloid cells was also shown to control the infl ammatory response through the regulation of the metabolic switch to glycolysis ( 44 ) , and contribution to T-cell suppression in the tumor microenvironment ( 45 ) . Myeloidspecifi c HIF-2α promoted tumor cell proliferation and progression in murine hepatocellular and colitis-associated colon carcinoma models ( 46 ) . In addition, the transcription factor Ets2 in myeloid cells is important in metastasis, as its deletion decreased the frequency and size of lung metastases in three different mouse models of breast cancer metastasis, which is mediated through inhibition of a gene program for angiogenesis ( 47 ) . Recently, mice with myeloid-specifi c deletion of HuR, a RNA-binding protein that regulates mRNA transcription and translation, displayed enhanced sensitivity to endotoxemia, rapid progression of chemical-induced colitis, and increased severe susceptibility to colitis-associated cancer through increased infl ammatory cytokines and enhanced chemokine (C-C motif) receptor 2-mediated macrophage chemotaxis ( 48 ) . However, most of these reports did not focus on tumor metastasis. Of interest, the deletion of myeloid-specifi c VEGF-A resulted in accelerated tumor progression despite the fact that myeloid-derived VEGF-A is essential for the tumorigenic alteration of vasculature and signaling to VEGFR2, and these changes act to retard, not promote, tumor progression ( 49 ).
Our results provide insight into the molecular mechanisms for TGF-β regulation of myeloid cell tumor-promoting function ( Fig. 7C ) . First, TGF-β is produced in high levels by tumorassociated myeloid cells including Gr-1
+
CD11b
+ cells ( 10 , 50 , 51 ) . In fact, depletion of Gr-1 + CD11b + cells diminished the antitumor effect of TGF-β neutralization ( 20 ) . Deletion of Tgfbr2 signifi cantly decreased TGF-β1 production, which is not the case for TGF-β2 or TGF-β3 ( Supplementary Fig. S10B and S10C). In addition, the CD11b
+
Ly6G
+ myeloid cell subset that we found plays a critical role in the decreased metastasis in Tgfbr2 MyeKO mice showed signifi cantly higher expression of TβR2 compared with CD11b + Ly6C + and CD11b + F4/80 + cells (Supplementary Fig. S9C ). Thus, our data suggest that there is likely an autocrine and/or paracrine loop that enhances TGF-β1 production and signaling in myeloid cells through the TβRII in the CD11b + Ly6G + myeloid cell subset ( Fig. 7C ) .
Deletion or downregulation of TGF-β signaling in myeloid cells would disrupt TGF-β1 production. However, it is not clear whether TGF-β1 production directly converts the myeloid cells from a type I to type II phenotype or is the result of type II myeloid cell polarization. Second, myeloid TGF-β signaling is critical in tumor-associated immune suppression. The critical mediators downstream of TGF-β signaling include type II cytokines, arginase 1, and iNOS, which have a signifi cant impact on both systemic adaptive immunity and innate immunity in the lung ( Fig. 7C ) 
+ dendritic cells, which were not present in the tumor microenvironment. Apparently, deletion of Tgfbr2 decreased iNOS production in the splenic Gr-1 + CD11b + cells and improved systemic immunity, whereas deletion of Tgfbr2 also increased IFN-γ production in the lung-residing macrophages and neutrophils. This seems to be different from the observation that IFN-γ levels correlate with iNOS in macrophages ( 52 ) . We want to point out that these two effects are in fact on very different populations of cells (myeloid immune suppressor cells versus lung-residing macrophages/neutrophils) and in two very different organ environments (spleen versus lung). A number of studies support the idea that regulation of iNOS in vivo may depend on the relative tempo with which the infl ammatory and immune responses evolve. We believe this increased innate immunity in the lung may be important in the diminished tumor metastasis in Tgfbr2 MyeKO mice. A recent study reported that type I IFN-α/β selectively within the innate immune compartment is essential for tumor-specifi c T-cell priming and tumor elimination ( 53 ) . TAMs cross-talk with adaptive immune components ( 54 ) . We found that the critical mediators in the improved IFN-γ-producing CD8 + T cells in the Tgfbr2 MyeKO mice involve IL-4, IL-10, and TGF-β, as well as arginase 1 and iNOS. Overexpression of these factors in sorted Gr-1 + CD11b + cells with Tgfbr2 deletion decreased the number of IFN-γ + T cells ( Fig. 5A and B ) . 
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Gr-1 + CD11b + cells ( 12 ) . Our data suggest that an improvement in both systemic adaptive immunity and local innate immunity in the lung is important for the reduced metastasis observed in Tgfbr2 MyeKO mice. However, our data support that CD8
+ T cells play a prominent role in adaptive immunity that is critical in metastasis inhibition in Tgfbr2
MyeKO mice. Consistent with the observations in tumor-bearing mice, myeloid cells from the peripheral blood of patients with advanced-stage lung cancer also showed increased TβRII expression, suggesting the clinical relevance of our studies. Importantly, the transplant of Tgfbr2
MyeKO bone marrow into wild-type mice bearing 4T1 tumors signifi cantly increased survival and decreased lung metastasis. It is quite feasible with the current technology to manipulate TGF-β signaling in bone marrow-derived myeloid cells through viral vectorinduced recombination and bone marrow transplantation. This novel approach, by targeting myeloid TGF-β signaling, may overcome some of the problems of systemic application of small-molecule inhibitors of TβRII kinase or neutralizing antibodies that often have adverse effects in normal healthy tissues. This is particularly exciting in two respects: (i) clinical inhibitors have not shown high rates of tumor response, and deletion of Tgfbr2 in bone marrow-derived cells may provide a novel option that has not been described before; (ii) the fi nding that myeloid-specifi c TGF-β signaling is a signifi cant part of the tumor-promoting effects of TGF-β allows specifi c and effective targeting. This fi nding is particularly important because TGF-β functions as both a tumor suppressor and promoter. The reduced tumor metastasis that we have observed suggests that myeloid-specifi c Tgfbr2 deletion is likely to be effective in countering the tumor-promoting role of TGF-β. Taken together, our studies show that myeloid-specifi c TGF-β signaling is a signifi cant part of the tumor-promoting effects of TGF-β. This may provide therapeutic opportunities for new approaches to cancer therapy.
METHODS
Cell Lines and Generation of Tgfbr2
MyeKO Mice
Murine 4T1, MC26, B16, and LLC cell lines were obtained from the American Type Culture Collection and kept in the liquid nitrogen when not in use. Cells were thawed, cultured, and passaged less than 6 months for experiments. These mouse cell lines have not been authenticated by the authors. The Tgfbr2 fl ox/fl ox mouse line was established as described previously ( 55, 56 ) . LysM-Cre mice (C57BL/6 and 129 background) were obtained from The Jackson Laboratory. 
Flow Cytometry and Cell Sorting
Single-cell suspensions were made from peripheral blood, lymph node, spleen, thymus, and bone marrow from normal and tumorbearing mice ( 16 ) , as well as tumor and lung tissues ( 57 
Immunofl uorescence Staining
The sorted myeloid cells were centrifuged on cytospin slides, fi xed with 4% paraformaldehyde, and incubated with a rat polyclonal anti-TβRII antibody (Santa Cruz Biotechnology) followed by Alexa Fluor 488 goat anti-rat or 594 goat anti-rabbit (Invitrogen) antibodies. 
TGF-b1 ELISA
Cytokine Antibody Array
Gr-1 + CD11b + cells were sorted from Tgfbr2 MyeKO and Tgfbr2 fl ox/fl ox mice bearing 4T1 tumors. The proteins were extracted and a cytokine antibody array was conducted as per manufacturer's protocol (Raybiotech). The relative quantifi cation was determined by dot density using ImageJ software.
iNOS and Arginase 1 Functional Assays
Fluorescence-activated cell sorting (FACS)-sorted myeloid cells were cocultured with splenocytes from OT1 mice with the stimulation of OVA peptide [Youn and colleagues ( 32 ) ]. Cell culture supernatant was collected and subjected to nitrite assay using the Nitric Oxide Quantitation Kit (Active Motif). For arginase 1 functional assay, sorted myeloid cells (1 × 10 6 ) cells from the spleens of 4T1 tumor-bearing Tgfbr2 fl ox/fl ox and Tgfbr2 MyeKO mice were lysed in TrisHCl (pH 7.4) containing protease inhibitor cocktails and 1% Triton X-100. After centrifugation, cell lysate supernatant was analyzed for arginase activity with QuantiChrom Arginase Assay Kit (DARG-200).
Electroporation
MACS-sorted Gr-1
+ myeloid cells (2 × 10 6 ) from spleens of Tgfbr2 fl ox/fl ox and Tgfbr2 MyeKO mice were electroporated with overexpression plasmids of TGF-β1 (a gift from Dr. Lalage Wakefi eld, NCI, Bethesda, MD), IL-4 (pORF-mIL-4; InvivoGen), and IL-10 (pORFmIL-10; InvivoGen) using an Amaxa mouse macrophage nuclefector kit according to the manufacturer's instructions. ) from OT1 or CL4 transgenic mice at 6:1 ratios (splenocytes:myeloid cells). Overexpression of arginase 1 (Origene) and iNOS (a gift from Victor Laubach, University of Virgina, Charlottesville, VA) in myeloid cells isolated from Tgfbr2
IFN-g ELISPOT
MyeKO was done using a mouse macrophage nucleofector kit (Lonza). Irradiated splenocytes (2,000 rad; 5 × 10 5 ) were added as antigen-presenting cells. OVA257-264 peptide or HA 518-526 peptide (1 μg/mL) was added as a stimulator. After 24-hour culture, IFN-γ ELISPOT assays were conducted and spot numbers were counted as described earlier.
Western Blotting
Gr-1
+
CD11b
+ cells sorted from the spleens or lung tissues of normal or 4T1 tumor-bearing mice were lysed and analyzed by Western blotting. Primary antibodies included TβRII, pSMAD2, SMAD2 (Cell Signaling Technology), and β-actin (Sigma).
Quantitative Real-Time PCR
Total RNA was extracted from sorted Gr-1 + CD11b + cells or subsets using an RNeasy Mini kit (Qiagen), and cDNA was synthesized using the Invitrogen SuperScript First-Strand Synthesis System. Relative gene expression was determined using a Bio-Rad iCycler-iQ SYBR Green PCR kit. Primer sequences are available upon request.
Spontaneous and Experimental Metastasis
For orthotopic metastasis, mammary tumor 4T1 cells (5 × 10 4 ) were injected into the #2 MFP. The numeration referred to: the neck to the groin, the neck (#1, left and right), the arm (#2, left and right), the thoracic (#3, left and right), and abdominal (#4 and #5, left and right). Mice were sacrifi ced 28 days later. For the B16 orthotopic model, 1 × 10 6 B16 cells were injected subcutaneously, tumors were removed at day 16, and mice were euthanized at day 37. For experimental metastasis, mice received a tail vein injection of 4T1 cells (2 × 10 5 ), LLC cells (2.5 × 10 5 ), MC26 cells (2 × 10 5 ), or B16 cells (2 × 10 5 ). Tumor size was measured at 2-to 3-day intervals using calipers as: volume = length × (width) 2 × 0.5. The number of lung metastases was evaluated as described previously ( 58 ) or by hematoxylin and eosin staining of lung sections when mice died or became moribund, or when the primary tumors reached a size of 2.0 cm in diameter.
IFN-g Neutralization
4T1 cells (5 × 10 4 ) were injected into #2 MFP of Tgfbr2 fl ox/fl ox and Tgfbr2
MyeKO mice. The mice were treated with IFN-γ-neutralizing antibody XMG-6 or IgG control by intraperitoneal injection. Dosage: 1 mg antibody or IgG per mouse on days 1, 3, and 6; and 0.5 mg on days 9, 12, 15, 18, 21, 24, and 27. Mice were sacrifi ced on day 28 after tumor injection. Lung metastases were evaluated as described earlier and tumors were weighed.
CD8 + T-Cell Depletion
For in vivo depletion of CD8 + T cells, CD8α-neutralizing antibody (2.43 clone) and IgG2b (100 μg/mouse) were intraperitoneally injected every 2 days starting from the day 0 of 4T1 injection until the mice were sacrifi ced and evaluated for lung metastasis.
Myeloid Cell Reconstitution
The 
CD11b
+ cells for the last three injections. This is based on an increase of those myeloid cells in the peripheral blood over the time after tumor injection. Mice were euthanized on day 20. Lung metastasis was evaluated.
Ex vivo Pulmonary Metastasis Assay
B16BL6-GFP cells (5 × 10 5 ) were coinjected with sorted myeloid cells (10 6 ) through the tail vein. Mice were euthanized 5 minutes after injection, and the lungs were infused with agarose as described previously ( 59 ) . Lung sections were sliced (1-2 mm thick) and placed on Gelfoam (Pfi zer-Pharmacia & Upjohn Co.) for culture. LEICA-DM IRB fl uorescent inverted microscope (Leica) and Retiga-EXi Fast 1394 Mono Cooled CCD camera (QImaging) were used to capture GFP-positive cells at ×10 magnifi cation. The area was quantifi ed by OpenLab software (Improvision; ref. 59 ) . For the effect of IFN-γ-defi cient myeloid cells on metastasis, the Ly6G cells were sorted from IFN-γ knockout mice bearing B16 melanoma (C57BL/6 background). The cells were then injected with B16 cells through the tail vein. The lung section culture was conducted as described earlier. Metastasis was evaluated after 2 to 3 weeks.
Bone Marrow Transplant
4T1 cells (5 × 10 5 ) were injected into the #4 and #5 MFP of wild-type Balb/c mice (recipients). Fifteen days later, the primary tumors were surgically removed and weighed. The mice were left to recover until day 34 after tumor injection, which allowed them to develop invasive tumors and metastasis. On day 34, these mice were irradiated (900 cGy). Bone marrow cells (5 × 10 5 ) from Tgfbr2 MyeKO mice or Tgfbr2 fl ox/fl ox control mice (donor mice) were injected into the tail vein of recipient mice in 100 μL PBS. Acidifi ed water (pH 1.3 to 2.0), autoclaved food, and autoclaved cages were used for the recipient mice for 2 weeks after irradiation. Lung metastases were evaluated starting on day 63.
Statistical Analysis
GraphPad Prism v5.04 was used for the graphs and for statistics. All data other than indicated were analyzed using the Student t test and were expressed as mean ± SE. Differences were considered statistically signifi cant when the P value was less than 0.05.
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